Answers are grounded in this paper and cite their sources.
Bioequivalence analysis reveals that smoking alters montelukast pharmacokinetics, suggesting implications for asthma management.
Background: Montelukast is one of the main therapeutic agents used for asthma management. Its therapeutic effectiveness is greatly influenced by the expression of metabolic enzymes and/or transporters involved in its disposition. Objectives: To assess the effect of smoking on montelukast pharmacokinetics in four bioequivalence studies against the reference drug Singulair®. Methodology: Data were extracted from bioequivalence studies to compare 10 mg generic Montelukast to Singulair® the originator. Primary pharmacokinetic parameters, maximum plasma concentration (Cmax) and area under the curve (AUC0-inf and AUC0-t) were calculated using Kinetica®. Analysis of Variance was performed to compare montelukast pharmacokinetics between smokers and non-smokers. Statistical significance was set at P ≤ 0.05. Results: Mean± SD montelukast Cmax (ng/mL) was 397.1 ± 125.7 in non-smokers compared to 352.8± 133.9 in smokers. Significant alterations in montelukast Cmax (P= 0.0206), AUC 0-t (ng. h/L) 2335 ± 111, P= 0.0016, and AUC 0-inf (ng. h/L) 2509 ± 1163, P= 0.0015 were observed in the study participants who are smokers. Conclusion: Despite the minimal fold-decrease in montelukast pharmacokinetic parameters in smokers compared to non-smokers, this might have a profound clinical impact on the therapeutic effectiveness of montelukast in patients.
No takes yet. Share an insight, caveat, or question.
Said et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: